Hydromorphon-Hcl Heumann (Hydromorphone Hydrochloride)

Hydromorphone is an opioid analgesic used to manage pain conditions that involve the central nervous system.

• Moderate to severe pain: provides effective relief when non‑opioid analgesics are insufficient.
• Postoperative pain: reduces pain intensity after surgical procedures.
• Cancer pain: alleviates persistent pain associated with malignant disease.

• Hydromorphone acts as a full agonist at the µ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to neuronal hyperpolarization. This suppresses transmission of nociceptive signals and alters pain perception, producing strong analgesic effects.

Hydromorphone may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea
• Constipation
• Drowsiness
• Dizziness
• Dry mouth
• Sweating

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Seizures
• Adrenal insufficiency
• Anaphylaxis
• Dependence or addiction

When prescribing hydromorphone, clinicians should observe several safety precautions to minimize risk.

• Assess pain severity: confirm that opioid therapy is appropriate for the patient’s level of pain.
• Evaluate respiratory function: monitor for signs of respiratory depression, especially in opioid‑naïve individuals.
• Review medical history: consider comorbidities such as severe asthma, sleep apnea, or head injury.
• Avoid concurrent CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol.
• Educate patients on dependence: inform about the risk of tolerance, dependence, and withdrawal.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Hydromorphone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with other opioids: may cause additive respiratory depression.
• Benzodiazepines or barbiturates: increase risk of profound sedation and respiratory compromise.
• Monoamine oxidase inhibitors (MAOIs): can precipitate severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Anticholinergic agents: may exacerbate constipation.
• Diuretics: can enhance orthostatic hypotension.
• Antidepressants (SSRIs, SNRIs): monitor for serotonin syndrome signs.